NYSE:ANRO Alto Neuroscience Q4 2025 Earnings Results & Report $22.68 +0.97 (+4.47%) Closing price 03:59 PM EasternExtended Trading$22.63 -0.05 (-0.22%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Alto Neuroscience beat analyst earnings expectations in its Q4 2025 results, released March 16, 2026. The company reported EPS of -$0.45 versus the -$0.56 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 16, 2026TimeBefore Market OpensConference Call7:00 AM ET Alto Neuroscience EPS ResultsActual EPS-$0.45Consensus EPS -$0.56Beat/MissBeat by +$0.11One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersAlto Neuroscience Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAlto Neuroscience's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Alto Neuroscience Q4 2025 Earnings FAQ Did Alto Neuroscience beat earnings estimates for Q4 2025? Alto Neuroscience (NYSE:ANRO) reported earnings of -$0.45 per share for Q4 2025, beating the consensus estimate of -$0.56. The report was announced on Monday, March 16, 2026. When is Alto Neuroscience's next earnings date? Alto Neuroscience's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Alto Neuroscience on the company's earnings history page. Alto Neuroscience Earnings HeadlinesAlto Neuroscience: Doubts Around Depression Candidate Merit Downgrade To Hold1 hour ago | seekingalpha.comAlto Neuroscience (NYSE: ANRO) CFO sells shares under trading planOctober 5, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 15 at 1:00 AM | InvestorPlace (Ad)Alto Neuroscience (NYSE:ANRO) Stock Price Down 5.6% Following Insider SellingOctober 4, 2026 | americanbankingnews.comAlto Neuroscience Announces Participation in Upcoming Investor ConferencesSeptember 9, 2026 | businesswire.comAlto Neuroscience Promotes Smith to President, CFOAugust 27, 2026 | tipranks.comSee More Alto Neuroscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alto Neuroscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alto Neuroscience and other key companies, straight to your email. Email Address About Alto NeuroscienceAlto Neuroscience (NYSE:ANRO) is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and neurological disorders. The company seeks to use neuroscience, digital health tools and biological and behavioral biomarkers to identify patient subgroups that may respond to specific treatments. Alto’s pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions. Its development programs are designed to address limitations of conventional psychiatric treatment by matching therapies to patient characteristics and measuring treatment response through objective data. The company’s drug candidates remain investigational and are subject to clinical and regulatory evaluation. Founded by psychiatrist and neuroscientist Amit Etkin, Alto Neuroscience is headquartered in the United States and conducts its research and clinical development activities through collaborations and clinical studies primarily involving U.S. patients and institutions. The company is listed on the New York Stock Exchange under the symbol ANRO.View Alto Neuroscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
